Further evidence of the adverse prognostic effect of PIK3CA mutations in HER2-positive breast cancer was provided in a large randomized Phase III study of patients receiving docetaxel in combination with trastuzumab plus placebo or docetaxel in combination with trastuzumab plus pertuzumab. This evidence concerns the gene ERBB2 and breast cancer.